GBMA welcomes infliximab biosimilar listing

rheumatoid arthritis
The Generic and Biosimilar Medicines Association has welcomed the approval of biosimilar infliximab, Inflectra. Inflectra is the first biosimilar infliximab to be approved in Australia, providing an alternative, affordable treatment option for patients suffering from a range of diseases including rheumatoid arthritis, psoriasis, ulcerative colitis and Crohn’s disease, says GBMA. A biosimilar is a biological

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Chilli receptors linked to satiety, disrupted in high-fat diet
Next Discount Drug Stores holds breast health clinics